Coagulation Tests: Understanding Blood Clotting
Your blood maintains a delicate balance between flowing freely and forming clots when needed. The coagulation cascade is a series of interconnected reactions that produce a fibrin clot to stop bleeding after injury — while natural anticoagulant proteins prevent unwanted clots from blocking healthy blood vessels. Coagulation blood tests measure how well this system is working, helping doctors diagnose bleeding disorders, monitor anticoagulant therapy, screen for blood clots, and assess surgical risk. An imbalance in either direction can be life-threatening: too little clotting causes dangerous haemorrhage, while too much causes thrombosis.
How Blood Clotting Works
Blood clotting (haemostasis) occurs in three overlapping stages. Understanding these stages helps explain why different coagulation tests exist and what each one measures.
1. Primary Haemostasis
When a blood vessel is injured, platelets rush to the site and stick to the exposed collagen (adhesion). They then change shape and release chemical signals that recruit more platelets (activation and aggregation), forming a temporary “platelet plug.” This initial plug stops minor bleeding within seconds but is fragile and needs reinforcement from the coagulation cascade.
2. Coagulation Cascade
Two pathways — intrinsic (measured by aPTT) and extrinsic (measured by PT/INR) — converge in the common pathway to activate thrombin. Thrombin converts dissolved fibrinogen into fibrin strands that weave through the platelet plug, creating a stable, mesh-like clot. Factor XIII then cross-links the fibrin to make it even stronger. This entire cascade involves over a dozen clotting factors working in precise sequence.
3. Fibrinolysis (Clot Breakdown)
Once healing is complete, plasmin breaks down the fibrin clot into fragments called fibrin degradation products — including D-Dimer. This process ensures that clots are temporary and do not permanently obstruct blood flow. Natural anticoagulant proteins (antithrombin, protein C, protein S) regulate the system throughout, preventing the cascade from activating where it should not.
Coagulation Test Reference Ranges
Reference ranges are based on RCPA guidelines and the most commonly used assays in Australian pathology laboratories. Always compare your results with the specific reference range printed on your report, as values may vary between laboratories and reagent manufacturers.
| Marker | Normal Range | Unit | Purpose |
|---|---|---|---|
Prothrombin Time (PT) | 11–14 seconds | seconds | Measures the extrinsic and common clotting pathways. Prolonged in warfarin therapy, liver disease, and vitamin K deficiency. |
International Normalised Ratio (INR) | 0.8–1.2 (normal) | ratio | Standardised PT result used worldwide to monitor warfarin. Therapeutic target depends on the condition being treated. |
Activated Partial Thromboplastin Time (aPTT) | 25–38 seconds | seconds | Measures the intrinsic and common pathways. Used to monitor heparin therapy and screen for haemophilia. |
D-Dimer (D-Dimer) | < 0.50 mg/L FEU | mg/L FEU | Detects fibrin degradation products. High sensitivity for DVT/PE but low specificity — best used to rule OUT thrombosis. |
Fibrinogen (Fibrinogen) | 1.5–4.0 g/L | g/L | The clotting protein converted to fibrin by thrombin. Low in DIC and liver failure; elevated in inflammation and pregnancy. |
Platelet Count (Platelets) | 150–400 × 10⁹/L | × 10⁹/L | Counts the cell fragments essential for clot formation. Low platelets (thrombocytopaenia) increase bleeding risk. |
Thrombin Time (TT) | 14–21 seconds | seconds | Measures the final step of clotting — fibrinogen to fibrin conversion. Prolonged by heparin, fibrinogen disorders, and FDPs. |
Bleeding Time (BT) | 2–9 minutes | minutes | Historical in-vivo test of platelet function. Rarely performed now — replaced by PFA-100 platelet function assays. |
Age-adjusted D-Dimer: For patients over 50 years, an age-adjusted cutoff of age × 10 µg/L FEU is increasingly used. For example, a 70-year-old would have a normal upper limit of 700 µg/L (0.70 mg/L) instead of the standard 500 µg/L (0.50 mg/L). This reduces unnecessary imaging by approximately 30% without missing significant clots.
Understanding INR and Warfarin Monitoring
The International Normalised Ratio (INR) was developed to standardise PT results across different laboratories. It is the primary test used to monitor warfarin (Coumadin/Marevan) therapy. Warfarin works by inhibiting vitamin K-dependent clotting factors (II, VII, IX, X), and the INR reflects how effectively it is doing so.
INR Target Ranges by Condition
| Condition | Target INR | Notes |
|---|---|---|
| Atrial Fibrillation (AF) | 2.0–3.0 | Most common indication. Reduces stroke risk by approximately 65%. |
| Deep Vein Thrombosis / Pulmonary Embolism | 2.0–3.0 | Standard treatment duration 3–6 months; longer for recurrent events. |
| Mechanical Heart Valve (aortic) | 2.0–3.0 | Bileaflet or tilting disc valve in aortic position without additional risk factors. |
| Mechanical Heart Valve (mitral) | 2.5–3.5 | Higher target due to greater thrombotic risk in the mitral position. |
| Antiphospholipid Syndrome | 2.5–3.5 | Higher target recommended following arterial thrombosis. Some patients require INR > 3.0. |
| Recurrent VTE on Warfarin | 2.5–3.5 (or switch) | Consider dose escalation or transition to a direct oral anticoagulant (DOAC). |
Testing Frequency
When starting warfarin: test every 1–2 days initially
Dose adjustments: test every 3–7 days until stable
Stable dose achieved: test every 2–4 weeks
Well-established therapy: test every 4–6 weeks (maximum 12 weeks)
After any illness, dietary change, or new medication: re-test within 3–5 days
Factors That Affect INR
Vitamin K-rich foods (spinach, kale, broccoli, Brussels sprouts) — lower INR
Cranberry juice, alcohol, and grapefruit — may raise INR
Antibiotics (especially metronidazole, fluconazole, co-trimoxazole) — raise INR
Paracetamol in high doses (> 2 g/day for several days) — raises INR
NSAIDs (ibuprofen, naproxen) — increase bleeding risk without changing INR
Herbal supplements (St John’s wort, fish oil, ginkgo) — variable effects
D-Dimer: DVT and PE Screening
D-Dimer is a fragment of cross-linked fibrin that appears in the blood when a clot is being actively broken down. It is one of the most commonly requested coagulation tests because of its role in screening for deep vein thrombosis (DVT) and pulmonary embolism (PE).
A normal D-Dimer in a low-to-moderate risk patient effectively rules OUT DVT and PE. The negative predictive value exceeds 99%. No further imaging is typically required.
An elevated result does NOT confirm a blood clot. D-Dimer rises in many conditions: surgery, trauma, infection, cancer, pregnancy, inflammation, and even normal ageing. Further imaging (ultrasound for DVT, CT pulmonary angiogram for PE) is needed to confirm the diagnosis.
Markedly elevated levels suggest significant clot burden and should be investigated urgently. Very high D-Dimer may also indicate disseminated intravascular coagulation (DIC), a medical emergency requiring immediate treatment.
D-Dimer naturally increases with age. Using the formula age × 10 µg/L for patients over 50 reduces false positives by approximately 30% while maintaining sensitivity above 97%. This approach is endorsed by major Australian and international guidelines.
Key principle: D-Dimer is a test for ruling out, not ruling in. A normal result in a clinically low-risk patient is extremely reassuring. An elevated result requires further investigation — it cannot diagnose a clot on its own.
Conditions Affecting Coagulation
Coagulation abnormalities can present as excessive bleeding, inappropriate clotting, or both simultaneously (as in DIC). The pattern of test results helps distinguish between these conditions and guide treatment.
Deep Vein Thrombosis / Pulmonary Embolism
Blood clots in the deep veins (DVT) or lungs (PE). D-Dimer has high negative predictive value — a normal result in low-risk patients effectively rules out VTE. PT/INR monitors warfarin treatment.
Haemophilia A and B
Inherited deficiency of factor VIII (type A) or factor IX (type B). The hallmark is a prolonged aPTT with a normal PT, because the intrinsic pathway is affected while the extrinsic pathway remains intact.
Von Willebrand Disease
The most common inherited bleeding disorder. Von Willebrand factor is essential for platelet adhesion. Bleeding time and aPTT may be prolonged, but many patients have normal routine coagulation tests.
Disseminated Intravascular Coagulation (DIC)
A life-threatening condition where widespread clotting consumes clotting factors and platelets. Expect prolonged PT, aPTT, and TT, low fibrinogen, very high D-Dimer, and low platelet count simultaneously.
Liver Disease
The liver synthesises most clotting factors. As liver function declines, PT prolongs first (factor VII has the shortest half-life). Advanced cirrhosis causes global coagulation failure.
Heparin Therapy Monitoring
Unfractionated heparin is monitored by aPTT (target 1.5–2.5× baseline). Low-molecular-weight heparin (enoxaparin) is monitored by anti-Xa levels in special populations such as renal impairment and obesity.
Who Should Have Coagulation Testing?
Urgent / Diagnostic Testing
Suspected deep vein thrombosis (leg swelling, pain, warmth)
Suspected pulmonary embolism (breathlessness, chest pain, haemoptysis)
Unexplained bleeding or prolonged bleeding after minor cuts
Excessive bruising without trauma
Pre-operative assessment before surgery
Suspected DIC (sepsis, obstetric emergency, major trauma)
Monitoring / Screening
Warfarin therapy — regular INR monitoring (every 2–6 weeks)
Heparin infusion — aPTT monitoring every 6 hours initially
Family history of bleeding disorders (haemophilia, VWD)
Recurrent miscarriage (antiphospholipid syndrome screening)
Known liver disease — assess synthetic function via PT
Thrombophilia screening after unprovoked DVT/PE under age 50
Related Blood Test Guides
When to Seek Emergency Care
Anticoagulant-related bleeding is a medical emergency. If you are taking warfarin, heparin, or a DOAC (rivaroxaban, apixaban, dabigatran) and experience any unusual bleeding, seek medical attention immediately. Bring a list of your medications and your most recent INR result.
Track Your PT/INR and Clotting Markers
Upload your blood test results to see INR, D-Dimer, fibrinogen, and platelet trends on interactive charts. Monitor your anticoagulant therapy over time and share professional reports with your haematologist — free forever for the first million users.
Get Started FreeMedical Disclaimer: This guide is for educational purposes only and does not constitute medical advice. Coagulation test results must always be interpreted by a qualified healthcare professional in the context of your symptoms, medical history, and current medications. Never adjust anticoagulant doses based on information found online.